Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 1998

View Archived Issues

Phase III study shows efficacy of becaplermin treatment for diabetic neuropathic ulcers

Selective inhibition of MMP activity as a novel treatment for DCM

Boston Scientific acquires CardioGene

Discovery Labs concludes phase Ib testing of vitamin D3 analogue; success reported

Ditropan XL shows favorable efficacy/side effect profile in phase III study

Belgian scientists on the way to developing a therapeutic vaccine for HCV?

New data indicate feasibility of gene therapy for HIV

Regeneron achieves milestone in Axokine development; receives payment from partner P&G

Cor Therapeutics describes selective factor Xa inhibitors

PDE V inhibitors for heart failure, impotence claimed by Merck KGaA

New immunosuppressants from Merck & Co. acting on potassium channels

Inhibitors of protein kinase GSK3 prepared at Chiron, U. of California

GH secretatogues from Fujisawa

Broad-spectrum antiviral compounds prepared at Astra

DuPont Merck now operating as DuPont Pharmaceuticals

Multiantigen malaria vaccine evaluated in phase I/II study

Panretin capsules and gel: positive clinical data presented at AIDS conference

Gilead announces phase II/III results for influenza neuraminidase inhibitor

Noven seeks U.K. approval for second-generation estrogen patch

Long-term safety and efficacy data presented for Enbrel

New herbal remedy for liver diseases improves liver function and quality of life

Vertex/Kissei select development candidate from p38 MAP kinase inhibitor program

FDA grants Ceresine expedited review status

Roberts and RiboGene sign development and marketing agreement for Emitasol

NeuroSearch and Meiji Seika collaborate with Pharmacia & Upjohn to develop NS-2710

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...